| |
Mean % change from baseline (95% confidence interval)
|
Pvalue*
(300 mg vs. 100 mg)
|
|---|
| |
Vandetanib 100 mg
|
Vandetanib 300 mg
| |
|---|
|
Primary variables
| | | |
|
iAUC60
|
--3.4 (--13.6, 8.1)
|
--4.6 (--13.4, 5.0)
|
0.429 (one-sided)
|
|
Ktrans
|
--4.6 (--22.4, 17.4)
|
--2.7 (--18.4, 16.2)
|
0.558 (one-sided)
|
|
Exploratory variables
| | | |
|
T2*
|
--2.2 (--7.1, 2.9)
|
7.3 (3.1, 11.7)
|
0.006 (two-sided)
|
|
LDDCE-MRI
|
16.1 (9.7, 22.9)
|
8.0 (2.9, 13.4)
|
0.029 (one-sided)
|
- iAUC60 initial area under the DCE-MRI contrast agent concentration--time curve after 60 s
- Ktrans volume transfer constant between blood plasma and extravascular extracellular space
- T2* effective magnetic transverse relaxation time
- LDDCE-MRI length of longest diameter of target lesion measured as part of the DCE-MRI acquisition protocol
- *The effect of vandetanib on MRI parameters was assessed using repeated measures ANOVA, which was fitted to the log-transformed baseline as a covariate and dose as a factor. Point and interval estimates were exponentially back transformed to provide the estimates of the % differences. The preplanned statistical comparisons were between the dose levels and not within dose levels. Only the least squares mean (95% CI) changes are reported within dose. See 'Statistical analyses' section for full details
